A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn’s Disease
Keyword(s):
2019 ◽
Vol 157
(2)
◽
pp. 440-450.e8
◽
Keyword(s):
2018 ◽
Vol 24
(suppl_1)
◽
pp. S2-S3
◽
Keyword(s):